Substance P impairs regulatory T cell function in dry eye disease, and blocking its receptor (NK1R) restores immune balance and ameliorates disease severity.
Restored Treg functionNK1R antagonist reversed substance P-mediated Treg suppression and ameliorated dry eye disease in mice
What the researchers found
Substance P promotes Treg dysfunction in DED, and NK1R antagonist treatment restores Treg function, suppresses Th17 responses, and ameliorates disease severity in mice.
Why it matters
Dry eye disease lacks targeted treatments. This study identifies substance P/NK1R as a druggable pathway that corrects the fundamental immune imbalance driving the disease.
The numbers in context
SP ↑ in DED; SP reduced Treg frequency/function; NK1R antagonist restored Tregs; Th17 suppressed; DED ameliorated
How the study worked
In vitro Treg cultures with substance P and NK1R antagonist, in vivo NK1R antagonist treatment in dry eye disease mouse model, flow cytometry for Treg and Th17 analysis.
Who was studied
DED mouse model and in vitro Treg cultures
What this study cannot tell us
Mouse model of DED. NK1R antagonist effects need validation in human DED. Exact mechanism of SP-mediated Treg suppression not fully elucidated.
How to read the evidence
Animal study with both in vitro mechanistic data and in vivo therapeutic validation. Strong preclinical evidence needing human confirmation.
When this study was published
Published in 2020. NK1R antagonists for ocular surface disease continue to be investigated.
The bigger picture
This connects neuropeptide signaling to autoimmune-type inflammation in the eye, suggesting NK1R antagonists could be a new treatment class for dry eye and potentially other mucosal surface diseases.
Questions still open
- Would topical NK1R antagonists be effective for dry eye in humans?
- Does substance P contribute to Treg dysfunction in other autoimmune conditions?
- Could NK1R antagonists be combined with existing dry eye treatments?
Common questions
What causes dry eye disease?
How could substance P blockers treat dry eye?
Read the original research
Restoration of Regulatory T-Cell Function in Dry Eye Disease by Antagonizing Substance P/Neurokinin-1 Receptor.
The American journal of pathology, 190(9), 1859-1866
Citation
Taketani, Yukako; Marmalidou, Anna; Dohlman, Thomas H; Singh, Rohan Bir; Amouzegar, Afsaneh; Chauhan, Sunil K; Chen, Yihe; Dana, Reza. (2020). Restoration of Regulatory T-Cell Function in Dry Eye Disease by Antagonizing Substance P/Neurokinin-1 Receptor.. The American journal of pathology, 190(9), 1859-1866. https://doi.org/10.1016/j.ajpath.2020.05.011